Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: A multi-center phase II study
| Autor: | Joe Shindoh, Masashi Kondo, Kazuyoshi Imaizumi, Syuichi Matsumoto, Hiroaki Kume, Yoshinori Hasegawa, Kenji Baba, Kenzo Takagi, Motoshi Ichikawa, Kensuke Kataoka, Yoshimasa Tanikawa, Yasunobu Noda, Kiyoshi Suzuki, Hiroyuki Taniguchi, Yuichiro Shindo, Ryujiro Suzuki |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine Cancer Research medicine.medical_specialty Lung Neoplasms Paclitaxel medicine.medical_treatment Phases of clinical research Docetaxel Gastroenterology Carboplatin chemistry.chemical_compound Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Lung cancer Survival rate Aged Chemotherapy Leukopenia business.industry Anemia Middle Aged medicine.disease Survival Analysis Anorexia Surgery Oncology chemistry Drug Resistance Neoplasm Disease Progression Female Taxoids Neoplasm Recurrence Local medicine.symptom business Follow-Up Studies medicine.drug |
| Zdroj: | Lung Cancer. 69:319-322 |
| ISSN: | 0169-5002 |
| DOI: | 10.1016/j.lungcan.2009.11.021 |
| Popis: | We conducted a phase II trial to evaluate the safety and efficacy of weekly paclitaxel in patients with resistant or relapsed non-small cell lung cancer (NSCLC) treated with docetaxel and carboplatin. Thirty-two NSCLC patients at a median age of 58.0 years (range 33–75) were enrolled. The Eastern Cooperative Oncology Group performance status scores (0/1/2) were 18/9/5, respectively. The majority of patients had adenocarcinoma (84%) and stage IV disease (81%). The response rate for the first-line chemotherapy was 28%. Paclitaxel was administered at a dose of 80 mg/m2 as an intravenous infusion 60 min weekly for 6 consecutive weeks of an 8-week cycle. All patients were assessable for response and toxicity. The median number of cycles administered was two (range 1–8), and the overall response rate was 15.6%. The median survival time (MST) was 10.6 months (95% CI = 8.2–12.5), while the 1-year survival rate was 37.5%, and the median progression-free survival was 4.9 months (95% CI = 3.0–7.1). Hematological toxicities (grade 3 or 4) were observed in 15 patients (46.9%) with leukopenia, and in 4 (12.5%) with anemia. Non-hematological toxicity was generally mild, though grade 3 anorexia was observed in 3 patients (9.3%). No treatment-related deaths were observed. In conclusion, second-line weekly paclitaxel is effective in NSCLC patients treated with docetaxel plus carboplatin and is associated with a tolerable toxicity profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect